News

Video

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

Author(s):

Arndt Vogel, MD

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Related Videos
Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung
Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINY-Breast12 primary results
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Richard Kim, MD, Moffitt Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Related Content
OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Suneel Kamath, MD, of Cleveland Clinic
November 27th 2024

Pancreatic Cancer Awareness Month Brings Attention to Growing Incidence and Treatment Advances

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health
November 27th 2024

Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression

Penpulimab Plus Anlotinib for Advanced HCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 26th 2024

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC